Innova Expands Biomolecule Conjugation Technologies to Simplify and Accelerate Research Processes
News May 24, 2007
Innova Biosciences Limited has announced the launch of an application using its Lightning-Link™ technology to provide a further addition to its conjugation capabilities and product offering.
Lightning-Link technology is used to join biomolecules forming ‘conjugates’, which are widely employed in bioscience, medical research as well as in diagnostic applications.
Innova has expanded its capabilities in a new application area, using Lightning-Link to speed up conjugation of the fluorescent protein phycoerythrin (PE) to disease-sensing monoclonal antibodies.
Using a flow cytometer, a machine which is widely available in research and clinical laboratories worldwide, the resulting PE conjugates can be used to detect a variety of disease disorders. To address these needs Innova has launched its new Lightning-Link PE kit.
Announcing the launch, Innova’s Chief Executive Officer, Dr Nick Gee said, “We are very pleased to add the Lightning-Link PE kit to the growing range of Lightning-Link conjugation kits and other research products we offer. What is unique about Innova’s method of conjugating biomolecules is its speed and simplicity. The traditional conjugation techniques can take up to two hours, whereas the Lightning-Link approach takes less than 30 seconds, saving the user significant time and effort.”
The Lightning-Link PE kit is a further addition to Innova's existing range of Lightning-Link conjugation kits, which include Lightning-Link HRP (Horse Radish Peroxidase) and Lightning-Link AP (Alkaline Phosphatase). These kits complement other Innova offerings which include a range of phosphate detection reagents, affinity resins and assay kits as well as Innova’s conjugation services. Innova has a pipeline of additional exciting conjugation products which will be launched throughout 2007.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019